On World Liver Day today, take a moment to reflect, your daily habits speak volumes about your liver's well-being. Fatty ...

Recent advances have marked a turning point for the treatment noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), with more therapies on the horizon to hopefully better address ...

MASLD, previously called ‘fatty liver disease’, is a ticking timebomb, affecting 30 to 40 per cent of adults – most of whom don’t know they have it ...

89bio, Inc. is a clinical-stage biotech focused on liver and cardio-metabolic diseases, with its lead drug candidate ...

A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like ...

Over the last year, 89bio’s stock has been somewhat volatile. Shares climbed past $10 earlier this year, but dropped under $6 ...

April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Madrigal Pharmaceuticals has hired a former Novartis executive to succeed its retiring founder as chief medical officer.

Bariatric surgery was associated with improved survival and appeared cost-effective over 10 years among patients with obesity and compensated cirrhosis, according to an analysis published in JAMA ...

Type 2 diabetes (T2D) is a complex and multifaceted disease that rarely exists in isolation. It is often entangled with a web of comorbid conditions, inclu | Immunology ...